HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients

被引：57

作者：

Likanonsakul S. ^{[1
]}

Rattanatham T. ^{[1
]}

Feangvad S. ^{[1
]}

Uttayamakul S. ^{[1
]}

Prasithsirikul W. ^{[1
]}

Tunthanathip P. ^{[1
]}

Nakayama E.E. ^{[2
]}

Shioda T. ^{[2
]}

机构：

[1] Bamrasnaradura Infectious Diseases Institute, Department of Disease Control, Ministry of Public Health, Nonthaburi

[2] Research Institute for Microbial Diseases, Osaka University, Osaka

来源：

AIDS Research and Therapy | / 6卷 / 1期

关键词：

Human Leukocyte Antigen; Nevirapine; Immune Reconstitution Inflammatory Syndrome; Thai Patient; 12th International Histocompatibility;

D O I：

10.1186/1742-6405-6-22

中图分类号：

学科分类号：

摘要：

Background: A high incidence of rash has been reported in HIV-1 patients who received the anti-retroviral drug nevirapine. In addition, several studies have suggested that polymorphisms of human leukocyte antigen (HLA) genes may play important roles in nevirapine-induced rash. The aim of the present study was to evaluate the effects of different HLA-C alleles on rash associated with nevirapine in patients who started highly active anti-retroviral therapy (HAART) containing nevirapine in Thailand.Results: A case-control study was carried out involving HIV-1 patients under treatment at Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand between March 2007 and March 2008. The study included all HIV/AIDS patients being treated with nevirapine-containing regimens. The study population comprised 287 HIV/AIDS patients of whom 248 were nevirapine-tolerant and 39 developed rash after nevirapine treatment. From the nevirapine-tolerant patients, 60 were selected as the control group on the basis of age, sex, and therapy history matched for nevirapine-induced rash cases. We observed significantly more HLA-Cw*04 alleles in nevirapine-induced rash cases than in nevirapine-tolerant group, with frequencies of 20.51% and 7.50%, respectively (P = 0.009). There were no significant differences between the rash and tolerant groups for other HLA-C alleles except for HLA-Cw*03 (P = 0.015).Conclusion: This study suggests that HLA-Cw*04 is associated with rash in nevirapine treated Thais. Future screening of patients' HLA may reduce the number of nevirapine-induced rash cases, and patients with alleles associated with nevirapine-induced rash should be started on anti-retroviral therapy without nevirapine. © 2009 Likanonsakul et al; licensee BioMed Central Ltd.

引用

共 35 条

[1]

Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators, N Engl J Med, 338, pp. 853-860, (1998)

[2]

Manosuthi W., Chottanapand S., Thongyen S., Chaovavanich A., Sungkanuparph S., Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy, J Acquir Immune Defic Syndr, 43, pp. 42-46, (2006)

[3]

Sabbatani S., Manfredi R., Biagetti C., Chiodo F., Antiretroviral Therapy in the Real World: Population-Based Pharmacoeconomic Analysis of Administration of Anti-HIV Regimens to 990 Patients, Clin Drug Investig, 25, pp. 527-535, (2005)

[4]

Havlir D., Cheeseman S.H., McLaughlin M., Murphy R., Erice A., Spector S.A., Greenough T.C., Sullivan J.L., Hall D., Myers M., Et al., High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection, J Infect Dis, 171, pp. 537-545, (1995)

[5]

Anekthananon T., Ratanasuwan W., Techasathit W., Sonjai A., Suwanagool S., Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study, J Med Assoc Thai, 87, pp. 760-767, (2004)

[6]

Stern J.O., Robinson P.A., Love J., Lanes S., Imperiale M.S., Mayers D.L., A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients, J Acquir Immune Defic Syndr, 34, SUPPL. 1, (2003)

[7]

Carr A., Cooper D.A., Adverse effects of antiretroviral therapy, Lancet, 356, pp. 1423-1430, (2000)

[8]

Kappelhoff B.S., van Leth F., MacGregor T.R., Lange J., Beijnen J.H., Huitema A.D., Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study, Antivir Ther, 10, pp. 145-155, (2005)

[9]

Gangar M., Arias G., O'Brien J.G., Kemper C.A., Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine, Ann Pharmacother, 34, pp. 839-842, (2000)

[10]

Pollard R.B.R.P., Dransfield K., Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection, Clin Ther, 20, pp. 1071-1092, (1998)

← 1 2 3 4 →